Clinical Trials Logo

Filter by:
NCT ID: NCT05858983 Recruiting - Clinical trials for Biallelic RPE65 Mutation-associated Retinal Dystrophy

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Start date: November 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of subretinal administration of FT-001 in subjects with biallelic RPE65 mutation-associated retinal dystrophy.

NCT ID: NCT05858944 Recruiting - Home Blood Pressure Clinical Trials

Home Blood Pressure Intervention in the Community Trial

Start date: March 23, 2023
Phase: N/A
Study type: Interventional

The primary purpose of the study is to explore whether a lower home blood pressure target (125/75 v.s. 135/85 mmHg) would be beneficial to elderly treated hypertensive patients in terms of reduced incidence of cardiovascular events. The study also aims to promote the application of standardised and information-based home blood pressure monitoring in community hypertension management.

NCT ID: NCT05858853 Completed - Hepatic Ascites Clinical Trials

Phase II/III of Recombinant Human Serum Albumin

Start date: May 25, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, double-blind, position-controlled, parallel group phase II/III clinical study of recombinant human serum albumin (rHSA) in cirrhotic ascites patients.

NCT ID: NCT05858827 Completed - Clinical trials for Artificial Intelligence

To Evaluate the Capability of an EUS Automatic Image Reporting System

Start date: May 10, 2023
Phase:
Study type: Observational

In this study, the EUS intelligent picture reporting system can automatically generate reports after reading videos of EUS examinations. This function can standardize the quality of endoscopic ultrasound image reporting and reduce the work burden of ultrasound endoscopists.

NCT ID: NCT05858814 Recruiting - Clinical trials for Acute Myeloid Leukemia

RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT

Start date: May 4, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and tolerability of RC1012 injection infusion in AML Patients after Allo-HSCT

NCT ID: NCT05858684 Recruiting - CAR-T Cell Therapy Clinical Trials

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Start date: May 11, 2023
Phase: Early Phase 1
Study type: Interventional

This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.

NCT ID: NCT05858567 Recruiting - Rectal Cancer Clinical Trials

Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma

RECMULRA-TNT
Start date: May 11, 2023
Phase: Phase 2
Study type: Interventional

Short-course radiotherapy combined with immunotherapy may bring revolutionary changes to the total neoadjuvant therapy mode for locally advanced ultra low rectal cancer to preserve the organs. In view of the shortcomings of the current otal neoadjuvant therapy model for locally advanced ultra low rectal cancer, we will explore the feasibility of a new model of short-course radiotherapy combined with immunotherapy, and develop a possible optimal plan based on the existing theoretical basis, namely "short-course radiotherapy + PD-L1 monoclonal antibody combined with CAPEOX chemotherapy for 8 cycles", and explore the efficacy and adverse effects of this model. The study will also attempt to explore the characteristics of the treatment beneficiary population, explore the characteristics of the treatment beneficiary population by multi-dimensional tumor and microenvironmental information through multi-omics sequencing analysis, attempt to build an efficacy prediction model, early screening of the treatment beneficiary population for precise treatment, and thus explore a new model of radiotherapy combined with immunotherapy for the poplation who can be achieved organ preservation.

NCT ID: NCT05858385 Recruiting - Clinical trials for Nasopharyngeal Carcinoma by AJCC V8 Stage

Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

Start date: September 22, 2022
Phase:
Study type: Observational

Exploring effective risk prediction models for severe Radiation-Induced Oral Mucositis (RIOM/RTOM), providing a research basis for mitigating oral radiation toxicity, and effectively improving the sensitivity of dentists in predicting the risk of severe RIOM in locally advanced nasopharyngeal carcinoma patients.Based on precise radiotherapy, it is proposed to extract OAR using the contour of local oral areas. Explore more accurate RIOM dose-response relationships.Exploring a new type of fusion classifier, by complementing the information between each base classifier, helps to maximize the utilization of the information contained in different factors to build a more objective, reliable, and efficient multi criteria decision-making based risk prediction model for severe RIOM. It use predictive models to identify key risk factors for severe RIOM and further validate the effectiveness of this risk factor in reducing the risk of severe RIOM on risk factors for severe RIOM identified by the predictive mode.

NCT ID: NCT05858242 Recruiting - Breast Cancer Clinical Trials

Study on Early Auxiliary Diagnosis and Postoperative Recurrence Monitoring of Breast Cancer

Start date: March 7, 2023
Phase:
Study type: Observational

This study screened and identified effective methylation markers in breast cancer, established a detection system for early screening and early diagnosis, and provided a research basis for the embryonic form of non-invasive breast cancer early screening products in later incubation. Then, the plasma ctDNA polygene methylation test was performed for early and middle stage breast cancer patients who were to receive radical surgery for initial treatment, and the predictive effect of postoperative plasma ctDNA methylation status on postoperative prognosis of breast cancer was discussed. In addition, the application value of dynamic monitoring of ctDNA methylation in plasma for postoperative recurrence risk monitoring was explored through regular postoperative follow-up of stage I-III breast cancer patients undergoing radical surgery.

NCT ID: NCT05858177 Completed - Clinical trials for Paraganglioma, Malignant

The Efficacy and Safety of Temozolomide in Patients With MPPGL

MPPGL
Start date: October 1, 2019
Phase: Phase 2
Study type: Interventional

Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor. Temozolomide (TMZ) is a novel oral alkylation chemotherapeutic agent. TMZ has been recommended in National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2019 for treating MPP patients.However, studies investigating TMZ efficacy in MPP patients are extremely limited. The largest study involved only 15 patients till date. The safety and efficacy of TMZ treatment in MPP patients need to be verified in larger studies.